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ABSTRACT 
Lymphovascular invasion (LVI) is associated with poor outcome in breast cancer (BC); 
however, its underlying mechanisms remain ill-defined. LVI in BC develops through 
complex molecular pathways involving not only the interplay with the surrounding 
microenvironment along with endothelial cells lining the lymphovascular spaces but also 
changes in the malignant epithelial cells with the acquisition of more invasion and migration 
abilities. In this review, we focus on the key features that enable tumour cell detachment 
from the primary niche, their migration and interaction with the surrounding 
microenvironment as well as the crosstalk with the vascular  endothelial cells, which 
eventually lead to intravasation of tumour cells and LVI. Intravascular tumour cells emboli 
survival and migration, their distant site extravasation, stromal invasion and growth are part 
of the metastatic cascade. Cancer cell migration commences with loss of tumour cells’ 
cohesion initiating the invasion and migration processes which are usually accompanied by 
the accumulation of specific cellular and molecular changes that enable tumour cells to 
overcome the blockades of the extracellular matrix, spread into surrounding tissues and 
interact with stromal cells and immune cells. Thereafter, tumour cells migrate further via 
interacting with lymphovascular endothelial cells to penetrate the vessel wall leading 
ultimately to intravasation of cancer cells. Exploring the potential factors influencing cell 
migration in LVI can help in understanding the underlying mechanisms of LVI to identify 








The outcome of breast cancer (BC) has significantly improved in recent years [1, 2]. 
However, approximately 30% of early stage BC patients develop distant metastasis within 
10 years following surgical resection of the primary tumours [3]. Lymphovascular invasion 
(LVI), which is defined as the presence of malignant cells within vascular or lymphatic 
spaces, is the major prerequisite for cancer progression and distant metastasis development 
[4-6]. Although LVI is strongly associated with advanced large-sized tumours, it is also 
observed in small early stage BC and tumours with varying degrees of differentiation. There 
is a strong correlation between lymph node and distant metastasis and clinically detectable 
LVI in the primary BC [7]. This suggests that LVI may occur early in the process of 
carcinogenesis but the more common clinically detectable LVI, which is often observed in 
larger tumours, occurs late following the accumulation of molecular alterations more than 
those required for invasion of the ducto-lobular basement membrane. This observation 
supports the hypothesis that LVI could be targeted in BC despite the presence of stromal 
invasion. However, the challenges of targeting LVI in BC stem from being multifactorial 
i.e. it includes complex molecular mechanisms that drive LVI such as; tumour cell invasion 
and migration and the interplay between BC cells and various cells and structures in the 
surrounding tumour microenvironment including extracellular matrix, stromal cells, 
immune cells and endothelial cells. However, understanding the role of cancer cell invasion 
and migration in the development of LVI and differentiation of LVI-related molecular 
alterations from these driving tumour cell invasion and migration as an early mechanism 
associated with malignancy is a ‘difficult’ but ‘beatable’ challenge. Among various LVI-
related pathways, this review focuses on the key features of cellular invasion, migration and 
their interaction with the surrounding microenvironment as principal factors leading to LVI. 
The liberation of cancer cells from their parent tumours is a primary and essential event for 
daughter tumour cells to colonise and resettle in a secondary site [8]. It has been proposed 
that the detachment of cancer cells from the primary tumour in breast cancer may be initiated 
by several genetic modifications in a sub-population of cells which enable them acquiring 
migratory potential [9]. In addition, several factors have been reported to influence tumour 
cell detachment such as enzyme activity, the rate of tumour growth and stress on cell release 
[10]. Beside the changes in cancer cell traits toward loss of epithelial and gain of certain 
mesenchymal markers, release of extracellular matrix (ECM)-degrading enzymes including 
matrix metalloproteinases (MMPs) accelerates the release of cells from the primary tumour 
tissue and subsequent invasion into tumour-adjacent tissues such as epithelial cell stratums 
and ultimately lymphatic vessels [11].  
Structurally, lymphatic vessels have exiguous cellular junctions between the lining 
endothelial cells (i.e. fenestrated) and are surrounded by occasional pericytes and lack 
basement membranes which typically surround capillary vessels. This fenestrated structure 
facilitates access of BC cells into lymphatic vessels [12]. Tumour cells release growth 
factors and angiogenic factors which play a crucial role in tumour progression, angiogenesis 
and LVI. Lymphatic endothelial cells, in turn, interact with tumour cells resulting in the 
secretion of small leucine-rich repeat proteoglycan, thus stimulating tumour cells to 
metastasise [13, 14]. However, the key molecular mechanisms underlying LVI, whether the 
alterations are in the tumour cells, in the endothelial cells or in both remain to be deciphered. 
Thus far, HER2 positive tumour cells have been found to be a promotor for invasion and 
migration in BC resulting in highly aggressive tumours with poor outcome [15, 16]. HER2 
has been strongly associated with LVI via disrupting the architecture of tumour cells and 
encouraging their migratory activity and epithelial mesenchymal transition (EMT) to lose 
their adhesion [17, 18]. Although the current standard therapeutic option is anti-HER2 
therapy such as Trastuzumab [15], Pertuzumab [19] or Lapatinib plus Capecitabine [16] 
have markedly improved the survival of HER2-positive breast cancer, the window is still 
open for further discovery of potential therapeutic targets such as those that can suppress 
LVI thereby preventing distant metastasis and improve patient outcome.  
CANCER CELL MIGRATION FROM A PRIMARY SITE TOWARDS 
LYMPHOVASCULAR SYSTEM 
Cancer cell migration is an early process in carcinogenesis and all invasive tumours exhibit 
migration ability. Cell migration is essential for the disease progression and can be 
considered the initial stage of both LVI and tumour metastasis. Studies by our group as well 
as others have shown the association between LVI and genes related to cancer cell migration 
in BC (Table 1) [20, 21]. Although these genes appear to play a role in cancer cell migration 
and invasion, their precise role in LVI as an additional biological event remains difficult to 
be summarised and the discrepancy of invasion/migration driving genes and those driving 
LVI  remains blurred. Furthermore, the currently ongoing mechanistic studies including 3D 
culture and co-culture with endothelial cells which allow investigating the intricate cell-cell 
and cell-matrix interactions may further help identifying the candidate genes or pathways 
driving LVI in BC.  
From a temporal standpoint, cell migration in BC is divided into three successive stages: 1) 
migration of the malignant epithelial cells (of the in situ disease) through breast duct 
basement membrane (invasion), 2) migration through tumour stroma and interstitium (local 
spread), and 3) migration through the lymphovascular wall (intravasation into 
lymphovascular spaces). With the success of the latter stage, tumour cells present within 
vascular spaces initiate the process of distant metastasis (Figure 1). As in a complex 
molecular mechanism, various factors, pathways and processes contribute in each step such 
as EMT of the invading tumour cells that might undergo changes in tumour cell motility and 
the interaction between tumour cells and microenvironment.  
During the stromal and ECM infiltration process, two distinct migratory patterns for tumour 
cells with potentially different molecular mechanisms have been documented: “single 
cancer cell migration” and “collective cancer cell migration” [22, 23]. 
Single Cell Migration 
In single cancer cell migration, individual cancer cells detach from the primary tumour mass 
and lose epithelial polarity, acquire morphological characteristics of mesenchymal cells 
through the process of EMT [24]. The physical process involved in single cell migration occurs 
when cancer cells migrate towards the lymphovascular channels through protease-dependent 
mesenchymal migration or protease-independent amoeboid-like migration. In the former, cells 
migrate based on the protease activity that cleaves ECM and facilitates cell entry into the 
vessels. In protease-independent amoeboid-like migration, cancer cells initiate mechanical 
forces that lead to promotion of cell permeation allowing them to cross the ECM instead of 
cleaving it [23]. Protease dependent mesenchymal migration is said to lead to slower tumour 
cell migration compared to protease-independent amoeboid-like migration [25].  
Collective Cancer Cell Migration 
In collective cancer cell migration, malignant cells destined for migration retain cellular 
cohesion to one another and migrate as detached clusters or remain connected to the primary 
tumour [26]. Force generation is a major prerequisite for collective cell migration where 
tumour cells advance by means of new protrusions. Clustering cancer cells develop integrin-
mediated focal adhesions and membrane protrusions, which bind to actin filaments and aid 
tumour migration. ECM degradation involves the creation of an invasion path by the leading 
cells in the infiltrating tumour border through β1 integrin-mediated focal attachment to ECM 
components such as fibronectin [27]. In addition, cytoskeletal adaptor proteins, including talin, 
paxillin, cortactin and vinculin, play a role in cancer associated fibroblasts (CAF) by mediating 
intracellular singling pathways and communication with tumour cells that promote cancer 
metastasis [23, 28] . 
Each of these migration patterns has specific characteristics and occurs through different 
biological mechanisms influenced by intrinsic vessel structures [22]. Collective cell migration 
is based only on the initial physical forces (protrusions) that are created by tumour cells 
themselves [22]. Furthermore, it usually executes vascular invasion through lymphatic spaces 
due to presence of several fenestrations between cellular junctions within the lymphatic vessel 
structure which facilities intravasation as compared to blood vessels [23]. On the other hand, 
single cell migration can utilise both biological (mesenchymal and/or ameoboid) and physical 
forces, and therefore can invade lymphatic vessels [23]. Vascular invasion assessment with 
collective cell migration has better performance due to the difficulty in identifying single 
tumour cell invasion [25]. This difficulty may be also attributed to the lower chance of single 
cells surviving as compared to collective cell migration, which produces a unique form of 
cortical actin filaments congregation around the cell junctions [23]. Proteins involved in the 
migration process are summarised in Table 2. 
The Role of Cellular Protrusions in Tumour Cell Migration 
Malignant cell protrusions, which consist of filopodia, lamellipodia and invadopodia, play 
a critical role in cancer cell migration via enhancing the physical forces leading to loss of 
adhesion between tumour cells (Figure 2). Tumour cell migration, which occurs as a result of 
re-modulation in cell-cell and cell-matrix adhesion, involves reorganisation of actin 
cytoskeleton and F-actin rich membrane protrusions at the tumour edge. Tumour protrusions 
are of two varieties namely, invasive and non-invasive protrusion. Non-invasive protrusion is 
fundamentally associated with protease-dependent mesenchymal migration such as in the 
bespoke EMT [23]. The invasive protrusion is involved in invadopodia which plays important 
roles in collective cancer cell migration and LVI in BC via upregulation of podoplanin 
without activation of EMT as reported in a recent clinical study recently [23, 29].  
Non-invasive protrusion involving lamellipodia and filopodia usually occur in association 
with single cell migration. Lamellipodia play an important role in cancer cell migration 
through loss of epithelial tissue cohesion with resultant tumour cell release from the primary 
tumour mass. Lamellipodia are produced by tumour cells where movement is initiated by 
forming new lamellipodia whilst promoting the loss of existing lamellipodia through 
forward contraction of the newly synthesised lamellipodia. This process helps tumour cells 
lose connection to the main tumour mass [30]. The focal adhesion adaptor proteins Scr and 
paxillin are used by non-invasive protrusion involved in lamellipodia and filopodia for ECM 
attachment via focal adhesion [31]. On the other hand, invadopodia affects the adhesion of 
cancer cells to the ECM which is crucial for invasion of lymphatic vessels, and the invasion 
of tumour cells to the vascular system [32]. Formation of invadopodia has been observed in 
various cancer cell lines including BC [27]. This structure is formed when the degradation 
of ECM and cell adhesion junctions occur concomitantly. An invadopodium is composed of 
three main parts: proteolytic, invasive and adhesive domains. The proteolytic domain largely 
contains proteases such as serine proteases e.g. A Disintegrin and Metalloproteinase 
(ADAM) and MMPs [23]. The invasive domain is located inside the connection between 
invadopodial protrusion and ECM and is responsible for the regulation of actin as well as 
actin-linked proteins including mammalian Ena (MENA) and cortactin [33]. MENA is 
involved in invadopodium maturation and migration via the regulation of cortactin 
dephosphorylation [33]. Protein interactions occurring inside the invasive domain cause 
polymerisation of actin filaments leading to generation of mechanical forces which drive 
the cell towards the lymphatic vessels. Lastly, the adhesive domain is present at the tumour 
periphery connected to the ECM and functioned by integrin-mediated adhesion [23].  
FACTORS ATTRACTING TUMOUR CELLS TOWARD THE LYMPHOVASCULAR 
SYSTEM 
Before discussing the interplay between tumour cells and ECM detachment from the primary 
mass, some factors that may direct or attract the tumour cells towards the endothelial cells 
whether in lymphatic are considered.  It has also been reported that the dysfunctional lymphatic 
network leads to elevation of the interstitial fluid pressure which in turn would be responsible 
for the directional locomotion of the migratory tumour cells toward the lymphatics at the 
tumour periphery [34]. By this mechanism, the tumour cells would be presented nearby the 
lymphatic system and passively increasing the opportunity of their intravasation into lymphatic 
channels. Nevertheless, attracting malignant cells towards both types of capillaries can also 
occur by active molecular mechanisms [35]. For example, vascular endothelial growth factor 
receptor-3 (VEGFR3) is solely expressed on lymphatic endothelial cells, and by binding to its 
ligand vascular endothelial growth factor (VEGF)-C, which is highly expressed in tumour cells, 
it may act as an attracting way which can also facilitate the tumour cells to leak into the vessels 
[35]. Previous reports have suggested that ECM also plays an important role in the process of 
cancer cell migration. MMPs are produced by stromal cells and are crucial for the 
progression of tumour cells owing to their capacity for ECM degradation remodelling and 
activation of matrix molecules and cytokines [36]. For instance, MMPs degrade matrix 
proteins and guide the tumour cells to lymphatic vessels causing generation of 
chemoattractant mitogen-like hepatocyte growth factor (HGF), which in turn activates 
MMP2 and MMP9 [37]. Tumour cells are attracted by HGF along a gradient, which leads 
to rearrangements in the actin cytoskeleton via Rho and Ras like GTPases. These GTPases 
subsequently regulate the assembly and organisation of protrusions made from actin 
cytoskeleton [38]. The role of HGF in this directionality has been also verified in vitro, 
where tumour cells and macrophages, when seeded together, show a random bi-directional 
migration pattern [39]. However, sustained directionality of tumour cells akin to what 
observed in vivo was retrieved in vitro when human umbilical vein endothelial cells were 
added to the culture within the same assay. These endothelial cells secrete the HGF required 
for the chemotactic gradient responsible for sustained directionality. However, when 
inhibiting the HGF signalling pathway between endothelial cells and tumour cells, the 
directional streaming of tumour cells become defective again [39]. 
INTERACTION WITH THE SURROUNDING MICROENVIRONMENT 
Although the initial molecular alterations that lead to invasion and metastasis begin in 
transformed BC cells, these processes cannot be completed without sustenance from and 
interaction with cells in the microenvironment which can either promote or suppress tumour 
cell migration and invasion. Subsequently, BC cells interact with various types of stromal 
and immune cells in their vicinity such as stromal mesenchymal cells, fibroblasts, 
myofibroblasts, adipocytes, immune inflammatory cells, endothelial cells and pericytes 
lining lymphovascular spaces for intravasation [22, 40, 41]. 
The interplay between tumour cells and tumour microenvironment is complex and the effect 
on cancer cell migration and invasion is mutual; being driven by both tumour cells and various 
components of tumour microenvironment. Many molecules secreted by non-malignant cells in 
the microenvironment could influence tumour cell behaviour and promote tumour migration 
specifically toward lymphatic vessels. These molecules include C-C chemokine receptor-7 
dependent paracrine effect and macrophages-derived Vascular Endothelial Growth Factor-C 
(VEGF-C) acting through autocrine mechanisms [42].  
The Role of Myoepithelial Cells and Fibroblasts  
Typically, myoepithelial cells are considered natural tumour suppressors in breast tissue 
through their action as tumour gatekeepers preventing cancer cell proliferation, survival, 
invasion, migration and metastatic spread [43]. However, following interaction with BC 
cells which are capacitated for invasion, these stromal and immune cells become modified 
and execute divergent function which promote BC cell migration and invasion. For instance, 
evidence indicates that CAFs ; modified stromal fibroblasts/myofibroblasts [44], promote 
tumour growth, migration and invasion via enhancing Wnt/β-catenin signalling, with 
subsequent activation of MMPs which degrade the vessel walls, thereby, facilitate BC cells’ 
migration towards vessels [45]. CAFs also express podoplanin and VEGF-C, which affect 
intratumoral micro-vessels, regulate cancer cell migration, influence malignant, 
inflammatory and endothelial cells and play pivotal roles in tumourigenesis and invasion 
[29]. In LVI, podoplanin positivity is more frequent than CD31 or CD34 positivity and is 
associated with the development of nodal metastasis and poor clinical outcome [29, 46]. 
CAFs are also a major source of N-cadherin in BC, thus affecting the tumour cells’ migration 
by prompting them to leave the primary site and start the migration process [47]. 
Furthermore, stromal fibroblast transformation into CAFs could be promoted through the 
loss of interleukin (IL)-6 hence, promoting BC cell migration and invasion [48]. 
The Role of Immune Cells and Inflammatory Mediators  
Inflammatory cells populating the tumour microenvironment play a critical role during LVI 
by enhancing cancer cell proliferation, migration, and invasion [49]. In invasive cancer 
microenvironment, tumour-associated angiogenesis and lymphangiogenesis tend to produce 
an interconnecting vascular organisation of lymphatics and blood vessels which facilitates 
tumour interaction with other cell types such as lymphoid, haematopoietic and mesenchymal 
cells, resulting in remodelling of the ECM [50, 51]. During tumour progression, malignant 
cells produce certain chemokines and cytokines that are mitogenic and/or chemoattractant 
for immune cells [50]. Infiltrating inflammatory cells, in turn, are activated to produce 
certain chemokines, cytokines and proteolytic enzymes which prompt tumour migration, 
invasion and survival, and also stimulate endothelial cells for neoangiogenesis and 
lymphangiogenesis [50, 51]. There is an increasing interest in the role of immune cells and 
tumour infiltrating lymphocytes (TILs) and their interaction with cancer cells to control 
tumour behaviour and response to therapy. Manipulation of this interaction is a fast growing 
field and several immune checkpoint inhibitors have been described in several solid cancers 
including BC which show highly promising results for therapy [52, 53]. There is sufficient 
evidence to demonstrate that moderate and intense inflammation is associated with 
improved prognosis in triple negative (TN) and HER2-positive BC [54-56]. TILs comprise 
several types of immune cells including tumour promoting and tumour suppressing cells. 
Cytotoxic T-cells (CD8+ T-cells) and natural killer T cells attack cancer cells and are 
considered to be tumour suppressor cells, whereas regulatory T-cells (CD4+, and FOXP3+ 
T-cells) inhibit immune responses to cancer cells and therefore can be considered as cancer-
promoting cells. Conversely, CD4+ T lymphocytes are able to promote invasion via 
activation of the epidermal growth factor receptor (EFGR) signalling pathway [57]. 
Moreover, a CD4+ T-cells fraction (Tregs) can inhibit anti-tumour immune response by 
suppressing effector T-cells and is responsible for producing several members of 
immunosuppressive cytokines family, including transforming growth factor-β and IL-10 
[58]. Therefore, CD4+ T-cells enhance the migration of tumour cells and facilitate LVI by 
inhibiting the anti-tumour response through significant chemokine production. 
Previous studies have demonstrated an association between LVI and tumour immune cell 
infiltration. For instance, LVI-positive squamous cell carcinoma of the tongue showed less 
CD4+ and CD8+ T-cells, and lower CD4+/FOXP3+ T-cell and CD8+/FOXP3+ T-cell ratios, 
indicating that tumour progression is associated with a shift towards a more 
immunosuppressive environment [59]. CD8+ T-cells induced by pre-existing tumour–
antigen, are downregulated by PD-1/ PD-L1 interactions [60]. Inflammatory factors are also 
involved in tumour migration through the release of pro-migratory factors. For instance, IL-
1β plays an important role in BC migration, adhesion to lymphatic endothelial cells and 
transmigration by activating unique chemokines and cytokines using the IL-1R [61]. IL-17A 
also promotes BC cell migration and invasion by activating certain intracellular signalling 
pathways [62]. 
Macrophages have been shown to promote tumour progression in BC [63]. Tissue 
macrophages play a pivotal role in tumour angiogenesis through their inherent characteristics 
such as flexibility and mobility in enhancing endothelial tip-cell anastomosis and by regulating 
excessive vessel sprouting. Thus they are suited to stimulate endothelial cells in different vessel 
segments to initiate contacts with other microenvironment molecules [64, 65]. Macrophages 
have been described to have both oncogenic and tumour suppressing functions. Once CD8+ 
T cells interact with tumour cell antigens, they produce interferon gamma that is responsible 
to perform a tumouricidal activity via inducing macrophage tumour killing activity and/or 
antigens [66], thereby suppressing LVI by decreasing their lymphatic microvascular density 
by producing extracellular vesicles which breaks down neighbouring mesenchymal tumour 
stroma [66, 67]. Contrasting this, macrophages also play a key role in promoting migration 
and invasion of tumour cells through production of epidermal growth factor which activates 
migration and invasiveness of malignant mammary epithelial cells [68]. Evidence from recent 
preclinical research studies has demonstrated that tumour-associated macrophages (TAMs) are 
one of the principal factors controlling tumour progression in many tumour types including BC 
[51]. TAMs are reported as having the greatest migratory capacity amongst haematopoietic 
cells [69]. TAMs have M2 macrophage phenotype (alternatively activated macrophages) in BC 
which requires CD4+ T-cell derived IL-4 for activate ion [70]. Once activated, TAMs can 
enhance angiogenesis via IL-1, MMP2 and VEGFs [64]. These proteases and growth factors 
released by macrophages have the ability to instigate tumourigenesis and promote tumour 
progression [71]. Moreover, in BC stroma, TAM-derived cytokines can stimulate tumour 
invasiveness by enhancing their adhesion to the ECM [72]. VEGF-C expression is strongly 
associated with TAM expression in BC and is strongly correlated with developing 
lymphovascular tumour density and LVI [73]. Macrophage migration inhibitory factor (MIF), 
a pleiotropic inflammatory cytokine, promotes the migration of BC cells via controlling 
CD74 expression and hypoxia-inducible factor-1 (HIF-1) [74]. Zhang et al, have indicated 
that MIF can regulate the level of VEGF-C in BC cells through activation of the MAP-
kinase signalling pathway [75]. This activation increases the invasive capacity of cancer 
cells by promoting TNF-α, leading to increased protease levels, and allowing tumour cells’ 
access into lymphatic vessels [76]. 
The Role of Hypoxic Microenvironment on LVI 
Hypoxia is also associated with cancer cell migration. HIF-1α drives tumour cell migration 
into a favourite ‘less hypoxic’ environment. This promotes tumour progression by 
enhancing tumour cell survival, invasion, anaerobic metabolism and angiogenesis [77]. 
VEGF, which is strongly associated with angiogenesis, is also regulated by HIF-1α [78]. 
Further, Schoppmann et al have suggested that HIF-1α is strongly associated with BC LVI 
together with VEGF-C/D and their receptor VEGFR-3 [77].  
CELLULAR ADHESION IN LVI 
Loss of tumour cell-cell adhesion is an essential step and early event in tumour cell migration, 
stromal invasion and intravasation. Most tumour cells lose their adhesion to the primary tumour 
cell mass and migrate by undergoing EMT. Conversely, several mechanisms including EMT 
and mesenchymal epithelial transformation (MET) are involved in tumour cell adhesion to 
lymphatic and or vascular endothelial cells [79]. MET is reversed EMT involving upregulation 
of E-cadherin and downregulation of N-cadherin. N-cadherin regulates the expression of 
vascular endothelial (VE)-cadherin in aggressive BC and hence promote tumour progression 
[79]. Several changes including upregulation of E-cadherin are responsible for N-cadherin 
paralysis that leads to downregulation of several mesenchymal markers and changes in several 
morphological features thus facilitating tumour cells’ adhesion to endothelial cells (due to 
reversal EMT to MET) [79]. Alternatively, VE-cadherin paralysis, which is a cadherin subtype 
produced by endothelial cells as a consequence of N-cadherin downregulation, affects 
epithelial markers and endothelial cell-cell junctions without influencing E-cadherin or MET 
process. Moreover, VE-cadherin is located on the cell membrane due to the disruption of VE-
cadherin clusters which activates VE-ectodomain encouraging its clustering at intracellular 
contracts and segregation of stable and mature junction [80]. Therefore, these effects lead to 
actin polymerisation or actomyosin inactivation resulting in changing the formation of inter-
epithelial adherens junctions. According to this evidence, the cytoskeleton regulates VE-
cadherin clustering and VE-cadherin regulates cytoskeletal organisation and barrier stability 
alternately [80]. Thus, VE-cadherin can assist tumour cells to adhere to lymphatic vessels via 
loss of lymphatic permeability control and through its effect on cytoskeletal integrity.  
The differences between E-cadherin, N-cadherin and VE-cadherin can be ascribed due to the 
different localisation of β-catenin. N-cadherin and VE-cadherin are expressed in the nucleus 
and cytoplasm respectively, while E-cadherin is expressed on the cell membrane. Therefore, 
E-cadherin levels are elevated in the presence of reduced N-cadherin expression leading to the 
repression of EMT regulators and transforming the invasive mesenchymal phenotype to an 
epithelial phenotype prompting tumour cells to adhere to lymphatic vessels and establish LVI 
as revealed in a recent clinical study [79]. 
Vimentin is related to the adhesion and migration properties of tumour cells [81]. Gilles et al 
have observed the accumulation of nuclear and cytoplasmic vimentin and β-catenin have a dual 
functional role in tumour cell migration and invasion by promoting a β-catenin/T-cell factor 
pathway in BC [82]. Moreover, vimentin expression is transactivated as a result of the 
interaction between β-catenin and T-cell factor (TCF)/ lymphoid enhancer factor-1 (LEF-1) 
transcription factor family. In mammary carcinoma cell lines where β-catenin is found on the 
plasma membrane, vimentin is downregulated while its level remains unchanged in the 
cytoplasmic and nuclear allocation of β-catenin [82]. Therefore, β-catenin acts as an 
EMT/MET regulator during cell migration. Liu et al have demonstrated that vimentin 
participates in the focal adhesion and cytoskeleton organisation and also regulates cancer cells 
mechanical homeostasis [83]. Hence, vimentin contributes to an aggressive tumour phenotype 
via LVI, because of its ability to enhance motility, change the configuration of cancer cells and 
downregulate tumour cell adhesiveness [84]. 
TUMOUR CELL INTRAVASATION 
Intravasation is the process whereby malignant cells cross the endothelial barrier and invade 
lymphatics across the basement membrane [26]. The rate of tumour cell intravasation is highly 
influenced by several factors involved in tumour cell invasion and migration and the interplay 
with the surrounding structures as described above [26]. Interaction between tumour 
microenvironment and tumour cells at the intravasation site can activate the reciprocal 
secretion of EGF. EGF executes its action through EGF receptor to promote tumour cell 
migration and invasion into the lymphatic channels via transactivation of EGFR signalling by 
EP4 receptor pathway which is involved in invadopodia formation [85]. Some authors have 
suggested that tumour cell intravasation plays a significant role in BC metastasis via attachment 
of endothelial cells to fibroblast-derived CXCL12 [86] where TGFβ augments intravasation by 
amplified penetration of microvessel walls [87]. Type IV collagenase, which can actively 
digest the ECM and basement membrane, enables malignant epithelial cells to migrate through 
the interstitial tissue and into lymphatic vessels facilitating the development of LVI [88]. 
Collection of BC cells can directly penetrate lymphatic vessels through the action of 
Cyclooxygenase (COX) 12 or COX15, which metabolises arachidonic acid to 12(S)-hydroxy-
eicosatetraenoic acid (12(S)-HETE). Exposure to 12(S)-HETE transiently reduces their VE-
cadherin expression resulting in the migration of these cells [89]. In vivo BC murine models 
have shown that the transcription factor Twist enhances the process of intravasation, acting as 
an EMT-inducing transcription factor and promoting the rate of haematogenous intravasation 
and bone metastasis [90]. Despite the documented importance of tumour intravasation into 
lymphatic/vascular spaces, the driving mechanisms controlling the process are still 
incompletely characterised and therefore warrants further studies. VE-cadherin regulates 
VEGFs and affects cancer cell migration through regulating actin-driven junction- associated 
intermittent lamellipodia [91]. Certain actions of VEGFs activate the C-C motif chemokine 
ligand 21 (CCL21), which interacts to C-C motif chemokine receptor 7 (CCR7) that is 
located on the vascular endothelial surface. The secretion of CCL21 is strongly affected by 
the upstream signalling of its receptor VEGFR3 and VEGF-C secretion by malignant cells 
[42]. Kim et al suggested that the Let-7a targeting of CCL21/CCR7 singling is a promising 
approach to prevent BC migration and invasion [92].   
VEGFs are also involved in tumour cell migration as regulators of BC proliferation 
enhancing and tumour cell escape from apoptotic signals. This characteristic makes VEGFs 
a potential target candidate in BC patients in the neoadjuvant setting [93]. Arai et al suggested 
that VEGFs also play an essential role in Trastuzumab therapy by minimising the allocation of 
tumour cells to lymphatic vessels in HER2-positive BC [94]. 
Podoplanin, which is expressed by lymphatic endothelial cells, induces the formation of a 
glycoprotein and is used as a specific lymphatic endothelial marker [95]. Podoplanin 
encourages migration, proliferation rate and invasiveness of malignant cells via increasing 
the RhoA activity [96]. Neri et al have shown that tumours with high expression of podoplanin 
have higher local migration and invasion than those with low podoplanin [97], therefore, 
suggesting podoplanin as a potential therapeutic target through preventing migration, using a 
podoplanin monoclonal antibody (NZ-1) and lectin (MASL) inhibition [98]. Knockdown 
studies with podoplanin siRNA have resulted in decreased cell proliferation and cell motility. 
Previous research study has shown that podoplanin could be a potential therapeutic target to 
prevent cancer cell migration via synthesis of phosphatase modular that may prevent cancer 
cell migration [99]. 
THE ROLE OF CANCER STEM CELL IN LVI 
Cancer stem cells (CSCs) play an important role in BC progression by regulating 
tumourigenesis and resistance to therapeutic regimens. CSCs are high malleability with 
reciprocal directions between stem and non-stem (differentiation) states [100, 101] with 
activation of the classical mesenchymal phenotype [102] and enhancement of the protrusive 
activation, which is a known migration hallmark, compared to differentiated cells [101]. 
Therefore, CSCs seem to control the alterations of the focal adhesion signaling dynamics that 
allow them to perform a rapid switching between migration/phenotype modes and that 
contributes in tumour cell movement through fibrous matrices and hence, initiate a symbiotic 
environment that increases metastatic potency [101]. Indeed, EMT plays a critical process 
underlying the role CSCs in the ability of cancerous cells to migrate, cause LVI and metastasise 
[103]. CSCs in in situ breast carcinomas can transform into migrating cancer stem cells (MCS), 
which have the ability to disseminate and form metastatic colonies, by EMT [104]. It has been 
demonstrated that some CSC biomarkers such as ALDH1, CD44, and CD133 promote 
lymphatic metastasis of cancer cells [105, 106].  A recent in vivo study demonstrated that CSCs 
play a key role in BC tumour progression by creating a permissive environment for the 
collective cancer migration and invasion processes via controlling E-cadherin and N-cadherin 
expression, and guide the invasion and metastasis [107]. It has also been demonstrated that in 
hypoxic conditions, CSCs can indirectly enhance angiogenesis and lymphangiogenesis by 
expression of angiogenetic and lymphangiogenic factors such as VEGFR2. VEGFR2 also 
alters the morphology of CSCs to elongated endothelial-like cells [101]. Another in vitro BC 
study [108] has indicated that CSCs expressed endothelial markers CD31, VEGFR2 and FVIII 
when cultured with the presence of VEGF. This data provides further support to the role of 
CSCs in the development of LVI.  
KEY LVI-RELATED BIOMARKERS  
There have been several studies attempting to identify target genes that play an essential role 
in LVI. Our group has recently published a bioinformatics study using RNA expression data 
to identify differentially expressed genes in LVI-positive and LVI-negative cases. Following a 
stringent approach, 99 genes were demonstrated as significantly associated with BC LVI 
whether being upregulated or downregulated [109]. 
In their study, Klahan et al [90] identified 86 differentially expressed genes with LVI in BC, 
including 37 downregulated and 49 upregulated genes. Among these genes, EPAS1 which 
stimulates the production of VEGF, and TNFSF11 which is a receptor activator of nuclear 
factor kappa-B ligand (RANKL); both enhanced mammary cell invasion, migration, and 
metastasis. Other genes included TNFSF11 and IL6ST that play important roles in cytokine-
receptor interaction, which is the most enriched pathway related to LVI.  
Focal adhesion kinase (FAK) is a cytoplasmic tyrosine kinase that is associated with a plethora 
of singling pathways fundamental to cell cancer migration, proliferation, death and tumour 
survival [110]. According to Golubovskaya et al, high FAK levels correlated strongly with 
aggressive BC subtypes such as TNBC as well as with LVI, hence FAK might be a target for 
therapeutic intervention in these patients [111]. Using pre-clinical mouse models of BC, a 
significant reduction in tumour growth was achieved by an anti-proliferative activity using a 
chemical inhibitor of FAK (BI 853520). Moreover, in-vitro and in-vivo suppression of FAK 
signalling in combination with chemotherapies improved chemo-cytotoxicity [112]. McCall et 
al showed that astaxanthin (ASX), a potent antioxidant, could play a critical role in preventing 
LVI by inhibiting tumour cell proliferation and migration through promoting apoptosis in BC 
cells compared with normal breast epithelial cells. ASX inhibits migration in the aggressive 
TN BC cell line [113] by decreasing the inflammatory mediators within the tumour 
microenvironment such as TNF-α, IL-6 and IFN-γ through NFκβ inhibition, therefore, 
rendering ASX a potential target to prevent LVI in BC [113]. Blocking migration would have 
a significant positive impact on patient outcome. Inhibiting the early events of cell migration 
from primary tumours into the circulatory or lymphatic systems will help reduce distant 
metastasis. Forkhead transcription factor family (FOXO) which are tumour suppressor 
regulating cell proliferation and promoting apoptosis in BC. Recent in vitro studies have 
demonstrated that expression of FOXO6 promotes BC migration and invasion by aiding EMT 
[114]. Elevated FOXO6 in BCs could be, at least in part, due to reduced activity of the 
PI3K/AKT pathway. Normal adult tissues exhibit decreased FOXO6 expression levels in 
contrast to BC which showed increased expression, thus it may be a potential candidate for BC 
therapy [115]. Others have indicated that FOXO3a is strongly associated with adverse 
clinicopathological parameters including EMT and poor patient outcome in TNBC, and plays 
an essential role in enhancing tumour cell migration via TGFβ1 triggered hepatocyte growth 
factor (HGF)-induced and MET-dependent migration in vitro [116]. The subcellular 
localisation of FOXO3a is important where phosphorylation of FOXO3a leads to its 
translocation from the nucleus to the cytoplasm [117]. For instance, in T-cell acute 
lymphoblastic leukaemia (T-ALL), FOXO3 is an indirect target of BMS-345541, selective 
IKK inhibitor. FOXO3a was reported to act as an EGFR inhibitor, and also increases 
chemosensitivity of cancer cells to lapatinib [118].  Consequently, FOXO6 and FOXO3a could 
be potential therapeutic targets to prevent LVI in BC.  
The current proteomic, transcriptomic and genetic evolution is not enough to draw a precise 
molecular roadmap for LVI. Although this difficulty may reflect the complexity of the whole 
process, this review has highlighted some important biological players at the molecular level 
to further assist deciphering the mechanistic overlap between the cancer cell migration and the 
surrounding microenvironment in BC LVI.  
FUTURE DIRECTIONS AND CONCLUSION 
Investigating a large cohort early-stage metastasis free (both node metastasis and distant 
metastasis) BC that contains subgroups of LVI negative and LVI extensive tumours using 
multiplatform high throughput molecular techniques looking at differentiational expressed 
genes and pathways could help eliminating the impact of metastasis on the candidate gene lists. 
Although LVI is considered an essential prerequisite for tumour metastasis, there are multiple 
LVI associated genes/proteins that do not generate metastasis. HER2-positive BC has been 
investigated in playing a significant role in LVI by enhancing the tumour microenvironment to 
support the tumour cell growth, stimulating invasion LVI and metastasis [119]. There are 
several pathways related to cancer cell migration which are essential to the prevention of 
metastasis, such as P120 Catenin, FAK, RhoA, Paxillin and P130CAS pathways. Furthermore, 
other pathways which affect cancer cell angiogenesis (STAT3 pathway), survival (PI3K 
pathway) and proliferation (RAS pathway) might be candidates for preventing BC 
LVI/metastasis. An in depth understanding of these pathways will facilitate the exploration of 
those genes responsible for LVI in BC, thus could be helpful pinpointing the target genes for 
therapeutic strategy and thus preventing BC metastasis.   
In conclusion, invasion and migration are important phenomena required for the process of 
LVI, are highly complex and overlapping, therefore, further mechanistic evaluation is 
necessary to explore the inter-relationship of these two processes in BC. This review has 
summarised the key factors associated with BC cell invasion and migration and the interaction 
with the microenvironment. We propose that further exploration of the candidate 
genes/proteins will be a tool to interrogate the metastatic cascade in BC and encourage a better 
understanding of LVI molecular mechanisms. Focusing on the migratory capacity and cancer 
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Figure 1: A schematic diagram for breast cancer cell migration process.  
The diagram shows the single and collective migration processes. In single migration process, 
individual tumour cells are detached and migrate through the surrounding environment and 
then invade the lymphovascular channels. This process in controlled mainly through epithelial 
mechanical transition process (EMT). In collective migration/invasion process; the tumour 
grows in nests and sheets that protrude through the surrounding tumour stroma and invade the 
blood channels in adherent tumour nests. EMT and mesenchymal epithelial transition (MET) 
factors play major roles in this process. Various tumour microenvironmental factors such as 
cancer associated fibroblasts (CAFs), podoplanin, tumour infiltrating lymphocytes (TILs), 
tumour associated macrophages (TAMs) and hypoxia inducible factor (HIF). Other endothelial 
related factors such as CXCL12, epidermal growth factors (EGFs), tumour growth factor beta 
(TGF-β), and COX15 are elevated during the process of intravasation.     
 
Figure 2: A schematic diagram illustrating types of cellular protrusions  
Filopodia and lamellipodia are non-invasive protrusions mechanisms which contribute in 
single cell migration by changing tumour cell cytoskeleton via initiating cell-physical forces 
resulting in loss of tumour cell-epithelial tissue adhesion. Invadopodia are invasive protrusions 
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